We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest close session, Merck (MRK - Free Report) was up +1.28% at $85.11. This move outpaced the S&P 500's daily gain of 0.85%. Meanwhile, the Dow experienced a rise of 1.36%, and the technology-dominated Nasdaq saw an increase of 0.72%.
The stock of pharmaceutical company has risen by 1.6% in the past month, lagging the Medical sector's gain of 6.01% and the S&P 500's gain of 2.38%.
The investment community will be paying close attention to the earnings performance of Merck in its upcoming release. In that report, analysts expect Merck to post earnings of $2.37 per share. This would mark year-over-year growth of 50.96%. Meanwhile, our latest consensus estimate is calling for revenue of $17.19 billion, up 3.18% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.93 per share and a revenue of $64.94 billion, signifying shifts of +16.73% and +1.21%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Merck. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.09% downward. At present, Merck boasts a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Merck has a Forward P/E ratio of 9.41 right now. For comparison, its industry has an average Forward P/E of 14.14, which means Merck is trading at a discount to the group.
It is also worth noting that MRK currently has a PEG ratio of 0.86. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals industry had an average PEG ratio of 1.57 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 159, this industry ranks in the bottom 36% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
In the latest close session, Merck (MRK - Free Report) was up +1.28% at $85.11. This move outpaced the S&P 500's daily gain of 0.85%. Meanwhile, the Dow experienced a rise of 1.36%, and the technology-dominated Nasdaq saw an increase of 0.72%.
The stock of pharmaceutical company has risen by 1.6% in the past month, lagging the Medical sector's gain of 6.01% and the S&P 500's gain of 2.38%.
The investment community will be paying close attention to the earnings performance of Merck in its upcoming release. In that report, analysts expect Merck to post earnings of $2.37 per share. This would mark year-over-year growth of 50.96%. Meanwhile, our latest consensus estimate is calling for revenue of $17.19 billion, up 3.18% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.93 per share and a revenue of $64.94 billion, signifying shifts of +16.73% and +1.21%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Merck. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.09% downward. At present, Merck boasts a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Merck has a Forward P/E ratio of 9.41 right now. For comparison, its industry has an average Forward P/E of 14.14, which means Merck is trading at a discount to the group.
It is also worth noting that MRK currently has a PEG ratio of 0.86. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals industry had an average PEG ratio of 1.57 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 159, this industry ranks in the bottom 36% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.